Biomarker Can Spot Alzheimer
Long before symptoms become visible in Alzheimer's, specific proteins in the blood and spinal fluid begin to drop off, that could then be used as biomarkers to track its progression. Screening patients at the clinically "silent" stage could proceed beside routine tests like colonoscopies and mammograms as another common tool of preventive medicine.
Familial Alzheimer's (FAD) and sporadic Alzheimer's are two of the basic types of the disease. The majority of such cases are sporadic, developing after the age of 65. The causes of this disease type are not completely understood. FAD is a rare variant caused by certain gene mutations that affects less than two per cent of Alzheimer's patients.
FAD is early-onset, developing before the age of 65, and it is inherited; all offspring in the same generation have a 50-50 chance of developing FAD if one of their parents had it. The markers the researchers tracked came from people with the FAD mutations, reports Eurekalet. "Since we knew that 50 per cent of first-degree relatives will inherit the same rare mutations, we were able to study the biochemical changes occurring in the cerebrospinal fluid," Mr John Ringman, who co-authored the study.
Free Sample Research Report on Biomarkers from BrandPrinciples.com - The complete market research report on Biomarkers focuses on the different types of biomarkers and their impact on various disease areas such as oncology, neurology, cardiology and other areas including metabolomic turmoil, arthritis, gynecology, oxidative stress, liver disease, pulmonary disease and aging. Provides global market analysis for biomarkers by prominent biomarker discovery technologies including imaging, genomics, proteomics, metabolomics, bioinformatics and other technologies. Includes estimates and projections for the total global biomarkers market. Projections and estimates figure for geographic regions including United States, Europe, Japan, Asia-Pacific, Canada and rest of the world. A total of 402 companies are covered that are engaged in biomarkers R&D, discovery, testing, and supply of products and services.
Familial Alzheimer's (FAD) and sporadic Alzheimer's are two of the basic types of the disease. The majority of such cases are sporadic, developing after the age of 65. The causes of this disease type are not completely understood. FAD is a rare variant caused by certain gene mutations that affects less than two per cent of Alzheimer's patients.
FAD is early-onset, developing before the age of 65, and it is inherited; all offspring in the same generation have a 50-50 chance of developing FAD if one of their parents had it. The markers the researchers tracked came from people with the FAD mutations, reports Eurekalet. "Since we knew that 50 per cent of first-degree relatives will inherit the same rare mutations, we were able to study the biochemical changes occurring in the cerebrospinal fluid," Mr John Ringman, who co-authored the study.
Free Sample Research Report on Biomarkers from BrandPrinciples.com - The complete market research report on Biomarkers focuses on the different types of biomarkers and their impact on various disease areas such as oncology, neurology, cardiology and other areas including metabolomic turmoil, arthritis, gynecology, oxidative stress, liver disease, pulmonary disease and aging. Provides global market analysis for biomarkers by prominent biomarker discovery technologies including imaging, genomics, proteomics, metabolomics, bioinformatics and other technologies. Includes estimates and projections for the total global biomarkers market. Projections and estimates figure for geographic regions including United States, Europe, Japan, Asia-Pacific, Canada and rest of the world. A total of 402 companies are covered that are engaged in biomarkers R&D, discovery, testing, and supply of products and services.
Source...